Focus Stocks
Eli Lilly - Shares Seeking Direction
Published on Thursday, 23 August 2012 05:00 Written by TradersHuddle Wire
New York, August 23rd (TradersHuddle.com) - Shares of Eli Lilly & Co. (NYSE:LLY) closed the trading
day lower by $0.04 or -0.09% from its previous close. Eli Lilly's price action formed what is considered to be a
doji close, where the open and close prices are very close to each other, mainly signaling an indecision between buyers and sellers.
Eli Lilly (NYSE:LLY) principal activities are to develop, manufacture and market pharmaceutical-based health care solutions. The company specializes in research and development, production and marketing of products for the treatment of diabetes worldwide, such as insulin and insulin delivery devices.. Some of the company's patents include Zyprexa, Prozac, Permax, Humulin, Evista, Humalog, Humatrope, Vancocin, Keflex, Nebcin , Lorabid, Gemzar, Tylan, and Rumensin.
Eli Lilly's trading range is defined by a trough, which marked calculated support at $42.20 and by a peak that set the resistance point at $44.53. These levels are closely watched by traders managing their positions.
Traders wanting to establish a position in Eli Lilly or traders that are already holding the stock can use the doji close to their advantage, since the pattern present a short-term pause in the stock's price action. This pause results in an entry point for traders depending of which way the stock resolves this short-term indecision.
The Doji is an important candlestick pattern that provides information on their own and as components in a number of important patterns. Doji form when a security's open and close are virtually equal. The length of the upper and lower shadows can vary and the resulting candlestick looks like a cross, inverted cross or plus sign. Alone, doji are neutral patterns.
Any bullish or bearish bias is based on preceding price action and future confirmation. In the case of Eli Lilly, given that the stock finished the session lower, bears should monitor the stock, as it could reverse if it manages to trade above its intraday high. Below a Doji illustration:

Related Articles
- From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients
- Lilly Oncology to Release New Pipeline Data at ASCO 2013
- Lilly Provides Update on CEO Dr. John Lechleiter
- Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
- Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
- Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
- Lilly Declares Second-Quarter 2013 Dividend
- Critical Alerts For Microsoft, Suncor Energy, Eli Lilly, TRW Automotive, and Embraer Released By InvestorsObserver
- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
- The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
Related Partner Headlines
- Eli Lilly And Stock To Go Ex-dividend Tomorrow (LLY) - TheStreet.com
- Eli Lilly And Company Stock Buy Recommendation Reiterated (LLY) - TheStreet.com
- Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases - Benzinga
- Eli Lilly And Company (LLY): Today's Featured Drugs Laggard - TheStreet.com
- Eli Lilly: Bearish Optons Trade - TheStreet.com
- Eli Lilly And Company Stock Buy Recommendation Reiterated (LLY) - TheStreet.com
- Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations - Benzinga
- European Commission Approves Lilly's Cialis for Benign Prostatic Hyperplasia - Benzinga
- Eli Lilly And Company (LLY): Today's Featured Drugs Laggard - TheStreet.com
- UPDATE: Eli Lilly Posts Downbeat Q3 Profit - Benzinga
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,251.61 Trade time:11:12AM EDT Value change:▼42.89 (-0.28%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,642.92 Trade time:11:12AM EDT Value change:▼7.59 (-0.46%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,443.62 Trade time:11:12AM EDT Value change:▼15.80 (-0.46%)In The Wires
-
Boston Scientific To Participate In The 38th Annual Deutsche Bank 2013 Healthcare Conference -
Food 4 Less/Foods Co Stores announce fundraising campaign to 'Honor Our Troops' -
Ralphs to Honor Our Troops -
L.B. Foster Company Declares Quarterly Dividend -
Grupo Simec, S.A.B. de C.V. announces repurchases of its own shares -
Kellogg Commits Support For Residents Of Moore, Okla. -
Georgia Power's lakes and recreation facilities offer activities for all this summer -
Iconix Acquires The Remaining 49% Interest In Ecko Unltd., and Marc Ecko Cut & Sew








